HonorHealth is promising high-quality care at the additional locations as well as \u201can expanded clinical knowledge base.\u201d<\/p>\n
Arizona-based health system HonorHealth is set to\u00a0acquire<\/a> a number of Evernorth Care Group primary care clinics across the Phoenix region.<\/p>\n Evernorth, a subsidiary of Cigna, operates clinics across the Valley region, providing integrated primary care services to about 80,000 patients. Those locations will become part of the HonorHealth system when the transaction closes, which is expected to happen in January 2026.<\/p>\n HonorHealth is promising high-quality care at the additional locations as well as \u201can expanded clinical knowledge base.\u201d<\/p>\n Todd LaPorte, HonorHealth\u2019s CEO, said the acquisition will enhance the health systems\u2019 service offerings and expand access to care for residents of the Valley.<\/p>\n “Evernorth Care Group has a 50-year history as a trusted leader in integrated care, delivering high-quality and affordable care to generations of families in the Phoenix area,” said LaPorte. “With nearly 100 years of healthcare expertise in Arizona, HonorHealth is proud to welcome these dedicated caregivers into the family.\u201d<\/p>\n Matt Totterdale, president of Evernorth Care Group, said his team is dedicated to a smooth transition for both patients and the care team.<\/p>\n “We\u2019re confident that HonorHealth is the right partner to continue our legacy and enhance care delivery for patients,\u201d he said.<\/p>\n Evernorth is fresh off the announcement that it\u2019s\u00a0investing heavily<\/a> in Shields Health Solutions, pumping $3.5 billion into the standalone specialty pharmacy company.<\/p>\n Shields was formerly a Walgreens company, but has been operating as a private, standalone company since its acquisition by New York-based private equity firm Sycamore Partners. That followed Sycamore’s\u00a0acquisition<\/a> of Walgreens Boots Alliance, which closed Aug. 28.<\/p>\n Evernorth’s investment in Shields is in the form of preferred stock and is not expected to have a material impact on The Cigna Group’s previously issued 2025 adjusted earnings per share guidance of at least $29.60.<\/p>\n Earlier this year Evernorth signaled that it will\u00a0expand its GLP-1 medication offerings<\/a> through the creation of Evernorth EnReachRx, a new patient support model for pharmacies that want to provide enhanced clinical services alongside the GLP-1 drugs.<\/p>\n \u00a0<\/p>\n<\/p>\n